Filament Health Corp. (FH.NE)
- CNW Group
FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS
Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that Chris Wagner has stepped down from his position as Director on the Company's board of directors due to the requirements of a new role, effective April 30, 2024.
- CNW Group
FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, will be participating in the Water Tower Research Fireside Chat Series on April 4, 2024, at 12:00 pm ET.
- CNW Group
FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, released its fourth quarter financial results and operational highlights for the period ended December 31, 2023.
